This prospective, single-center, randomized, double-blinded, placebo-controlled trial suggests that UC-MSCs administration via intravenous infusion is a safe and effective approach that could reduce exogenous insulin requirement and could alleviate insulin resistance in patients with T2DM. Here, INS is linked to Insulin resistance.